Genmab AS (GMAB):企業の財務・戦略的SWOT分析

◆英語タイトル:Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1654
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Genmab AS (GMAB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 26,2020 Passing of Genmab Annual General Meeting
Mar 10,2020 Genmab announces appointment of Anthony Mancini to newly created position of chief operating officer
Feb 21,2020 Genmab Board of Directors Chairman to Step Down
Feb 19,2020 Genmab publishes 2019 annual report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Genmab AS – Key Facts
Genmab AS – Key Employees
Genmab AS – Key Employee Biographies
Genmab AS – Major Products and Services
Genmab AS – History
Genmab AS – Company Statement
Genmab AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Genmab AS – Business Description
R&D Overview
Genmab AS – Corporate Strategy
Genmab AS – SWOT Analysis
SWOT Analysis – Overview
Genmab AS – Strengths
Genmab AS – Weaknesses
Genmab AS – Opportunities
Genmab AS – Threats
Genmab AS – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genmab AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 26, 2020: Passing of Genmab Annual General Meeting
Mar 10, 2020: Genmab announces appointment of Anthony Mancini to newly created position of chief operating officer
Feb 21, 2020: Genmab Board of Directors Chairman to Step Down
Feb 19, 2020: Genmab publishes 2019 annual report
Dec 05, 2019: Grant of restricted stock units to board members, management and employees and grant of warrants to employees in Genmab
Nov 06, 2019: Genmab announces financial results for the first nine months of 2019
Oct 30, 2019: David Eatwell to retire as chief financial officer of Genmab
Oct 14, 2019: Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
Sep 10, 2019: Genmab partners Tempus to identify new cancer targets
Sep 09, 2019: Genmab and Tempus enter into strategic collaboration agreement
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Genmab AS, Key Facts
Genmab AS, Key Employees
Genmab AS, Key Employee Biographies
Genmab AS, Major Products and Services
Genmab AS, History
Genmab AS, Subsidiaries
Genmab AS, Key Competitors
Genmab AS, Ratios based on current share price
Genmab AS, Annual Ratios
Genmab AS, Annual Ratios (Cont...1)
Genmab AS, Interim Ratios
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genmab AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Genmab AS, Performance Chart (2015 - 2019)
Genmab AS, Ratio Charts
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Genmab AS (GMAB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sunflower Electric Power Corp:企業の戦略的SWOT分析
    Sunflower Electric Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • PHINMA Energy Corp (PHEN):電力:M&Aディール及び事業提携情報
    Summary PHINMA Energy Corp (PHINMA), formerly Trans-Asia Oil and Energy Development Corp, is an oil and gas company that explores and develops oil and gas interest and geothermal energy. The company operates through business division such as power, wind energy, and energy resource development. Its p …
  • Reliance Industries Limited:企業の戦略・SWOT・財務分析
    Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • OraSure Technologies Inc (OSUR):企業の財務・戦略的SWOT分析
    OraSure Technologies Inc (OSUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Kia Motors Corporation (000270):企業の財務・戦略的SWOT分析
    Kia Motors Corporation (000270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Cebu Air Inc:企業の戦略・SWOT・財務情報
    Cebu Air Inc - Strategy, SWOT and Corporate Finance Report Summary Cebu Air Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Syngenta AG:企業の戦略・SWOT・財務情報
    Syngenta AG - Strategy, SWOT and Corporate Finance Report Summary Syngenta AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • HomeServe plc (HSV):企業の財務・戦略的SWOT分析
    HomeServe plc (HSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Nevro Corp (NVRO):医療機器:M&Aディール及び事業提携情報
    Summary Nevro Corp (Nevro) is a medical device company that offers products for the treatment of chronic pain. The company develops and commercializes senza spinal cord stimulation system (SCS), an evidence-based neuromodulation platform. Its solution for chronic pain also includes HF10 Therapy, whi …
  • Invenergy LLC:企業の発電所・SWOT分析2018
    Invenergy LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Air India Ltd.:企業の戦略・SWOT・財務分析
    Air India Ltd. - Strategy, SWOT and Corporate Finance Report Summary Air India Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Endo International Plc (ENDP)-医療機器分野:企業M&A・提携分析
    Summary Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies including Endo Pharmaceuticals, Paladin Labs, Par Pharmaceutical, …
  • Sunnova Energy Corporation:電力:M&Aディール及び事業提携情報
    Summary Sunnova Energy Corporation (Sunnova Energy) is engaged in providing solar power services to homeowners. The company is involved in installing and generating power. It offers solar service agreements such as EZ Pay PPA, PPA, EZ own plan, and solar lease plan. In addition, the company offers s …
  • UCB SA (UCB)-医療機器分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Owens & Minor Inc (OMI):医療機器:M&Aディール及び事業提携情報
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • TBG Diagnostics Ltd (TDL):製薬・医療:M&Aディール及び事業提携情報
    Summary TBG Diagnostics Ltd (TBG Diagnostics), formerly Progen Pharmaceuticals Ltd, is a molecular diagnostics company that develops, manufactures and markets molecular diagnostics kits, instruments and services. The company’s major products include nucleic acid extraction kits, HLA SBT typing kits, …
  • Karoon Energy Ltd (KAR):企業の財務・戦略的SWOT分析
    Karoon Energy Ltd (KAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Rentokil Initial plc (RTO):企業の財務・戦略的SWOT分析
    Rentokil Initial plc (RTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Evgen Pharma Plc (EVG):企業の財務・戦略的SWOT分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company focused on the development of sulforaphane-based compounds for the treatment of cancer and neurological disease. Its pipeline product SFX-01 targets STAT3 signalling to inhibit stem-like c …
  • VentiRx Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary VentiRx Pharmaceuticals Inc (VentiRx) is a biopharmaceutical company that develops and commercializes drugs for the treatment of respiratory, autoimmune diseases and cancer. The company develops toll like receptor 8 agonist and antagonists for the treatment of cancer, respiratory and autoimm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆